Seeking Alpha

success27

success27
Send Message
View as an RSS Feed
View success27's Comments BY TICKER:
Latest  |  Highest rated
  • Blog Watch: The Political Prophet On Obamacare Rollout [View instapost]
    obamacare is romney care and was originally conceived by
    a republican think tank in the 1990s.
    The reason republicans oppose it now is that they have been
    bought and paid for by insurance companies.
    Nov 26 08:40 PM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    Michael,
    Are you aware that Lance Armstrong Foundation has mentioned Onko along with CEA and blood testing for cancer?
    Armstrong won the Tour de France race 7 times and has cancer.
    This is a huge statement for Onko and Radient!
    As medical doctors become more and more aware of Onko AND also become aware of Radient's new University of Florida medical school and doctor who has developed cancer therapy, RADIENT is going to grow into a multi billion dollar company.
    Apr 27 07:07 AM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    Unless radient turns around its financial picture within a couple of weeks, it appears they are going to be selling in the pink sheets after being delisted on the AMX and not be in Nasdaq since their pps is less than $1.
    Apr 25 06:32 PM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    I think a buyout is in the works. There are too many positive and negative factors such as positive: Onko as good as or better than or in conjunction with CEA, the CIT from the UFla, medical doctor, spinoffs, Radient is hiring two new production employees, the negative news also would boost Radient toward being bought out, ie, lawsuits, de-listing, difficulty of meeting huge demands.
    Apr 19 02:40 PM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    First Radient said the lab results were due about the beginning of Jan. Then, when they changed that to the first quarter, a lot of selling started. Then, they said the end of the first quarter which is March 31. More selling.

    I wrote to Radient and asked them if that time element for reporting is on schedule. I have not heard back from them.
    I also asked if the India sales are bearing fruit.
    So, now I am asking if management is being led down the garden path by lab technicians and salesmen, or are they for real?
    Mar 28 02:45 PM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    Are these Radient doctors and scientists and screening programs
    all fraudulent?

    investorchannel.radien...

    investorchannel.radien...

    The only thing I do not understand is why investor news organizations like Marketwire, the Street, and Access, etc. are not putting these videos out instead of questioning RPC, or in the Street’s case, bashing RPC and selling short.

    Are there any large drug companies who have verified Radient’s products or tested them and found them lacking? It is not like Radient is selling snake oil by salesmen pretending to be doctors.
    Mar 27 09:35 AM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    I agree RnRS. For example, RPC could give notice of when it expects the independent analysis of Onko v. CEA to be released and its expected results.
    RPC could have a statement issued by Beart of his work at Mayo and what he sees of his own analysis using Onko.
    RPC could have its U of Fla doctor issue a layman's description of his work.
    RPC could tell investors of the progress it is making in sales.
    RPC could tell investors of progress of negotiations with large pharmasueticals like JnJ which is just starting the same kind of testing research that Onko already provides.
    RPC could tell investors exact facts without embellishment or name dropping of the Mayo clinic even though there were connections such as the testing of Mayo samples and Dr. Beart having been the head of a department of Mayo.
    Mar 22 12:07 PM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    Mr. Bryant, I am an investor in RPC. I have written to them with the following questions but have not had a response. I wonder if you have any better success with getting facts.
    1. When will the results of the Onko v. CEA tests be published and what do their doctors like Dr. Beart think of the comparison?
    2. What are their sales looking like, not just contracts but actual income from sales in various countries?
    3. Do they have any legitimate buyout or partnership offers or contracts?
    4. What is the status of various IPOs such as jade and the CIT work at the Univ. of Fla?
    It seems to me that RPC owes some news to its investors and not just playing defense with slams by the Street and Rosen and the NYSE de-listing bear raid.
    Mar 22 08:47 AM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    With radiation coming here from a Jap nuclear plant meltdown, it sure looks like Onko sure might be valuable to make early detection of cancers.
    Mar 15 11:40 AM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    Difficult decision, RnR. I am just like you, my friend presently with a loss from where I purchased. I would never tell you what I think you ought to do. I have thought about bailing out also. But I think to myself, why did I stay in up until now? And why would I bail out right before I am expecting positive results from the Onko v. CEA studies to be published at the end of this month?

    Yes, I believe the threat of a lawsuit and the lawsuit and the mocking articles by the Street and the possibility of de-lising are driving down the price as investors exit and shorts get gleeful.

    On the other hand, I agree with you that investors took stock in lieu of debt and other investors took stock for $7,900,000. I do not believe those who took stock are idiots. I believe they met with management, maybe even had their own medical doctors look at the Onko test kit and its comparison to CEA. I am hoping they also looked at the company's income ledgers before handing over their money and that they are expecting potential good revenues to be reported April 11.

    IF the comparison tests are positive and if Dr. Beart publishes his well respected opinion to the medical community, then EVEN if the revenues fall short of expectations and EVEN if the stock goes to the 20s, I am still going to hang on to the stock, perhaps even buy more at that price because I strongly believe that IF Onko is a good product and IF it and the CIT is marketed, and IF the spinoffs go to IPOs, then, I believe this stock, within this year is going to go into the single digits, and with good marketing it will go into double digits within a year.

    Like I wrote to dreamdiver, I have made a lot of mistakes. One of my mistakes took a bad hit. And I was ready to sell. But I looked at the fundamentals and sales and held it. It came back within a month and gave me excellent results. Then, I sold.

    The only thing I am peeved about with this stock is the NYSE halting trading on January 7 but letting large traders dump tens of millions of shares while not letting me bailout. And then, a few days later it issued a notice of de-listing. The NYSE fraudulently advertises that it is a fair and open market. That is a joke when it pulls stuff like it did in January.

    Another thing too is the possible eventual buyout or partnership with a big drug company or companies just like microsoft licensed its windows to many different computer companies but kept title to is software and made billions for its shareholders. RPC could do this, too.
    Mar 12 02:40 PM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    That last paragraph says a lot.
    I think RPC is in a very difficult business. If it were not very difficult, anyone could do this business.

    As it is, Dr. Beart sees a "tremendous growth trajectory" and "believes it offers a very promising future to physicians and their cancer patients, the business community and to RPC shareholders."

    Why would anyone call him a liar? What about the University of Florida medical doctor and CIT? What about a public study of Onko v. CEA testing? If this is all hype, they are sure going through a lot of effort for nothing.
    Mar 11 12:01 PM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    There is always the chance RPC will be de-listed because it has faced an uphill struggle with testing and marketing its products.

    Here is some more information from google, though, from one of their medical doctors.

    "Dr. Beart is a recognized specialist and expert in colorectal diseases and cancer, pioneer of the ileal pouch-anal anastomosis, and thought leader in the medical, scientific and research communities. Dr. Beart's primary experience and research includes continence preservation, colostomy avoidance and the identification and management of recurrent colorectal cancer. He has broad and deep clinical involvement in colorectal diseases, covering key areas that include colorectal cancer, chronic constipation and diarrhea, anorectal health care issues and diverticulitis, fecal incontinence, recurrent rectal cancer, inflammatory bowel disease and polyps.

    From 1976 through 1992 Dr. Beart worked at the Mayo Clinic in Rochester, Minnesota where he was Chairman of Department of Colorectal Surgery and pioneered the ileal pouch-anal anastomosis. He is a past president of the American Society of Colon and Rectal Surgeons, the Society of Surgery of the Alimentary Tract and the International Society of University Colorectal Surgeons. He had his surgical training at the University of Colorado and the Mayo Clinic. Dr. Beart graduated from Harvard Medical School in 1971 and is board-certified and recertified in General and Colorectal Surgery.

    According to Radient Pharmaceuticals Chairman and CEO Mr. Douglas MacLellan, "Dr. Beart brings extensive experience and expertise in oncology, specifically as it relates to colorectal health issues, diseases and cancer, to RPC that will be invaluable as we work to advance our In Vitro Diagnostic cancer test, vaccines and therapies. His innovative brilliance, success and deep relationship across the medical, research and scientific communities is a tremendous asset to our product commercialization and corporate development efforts. We are delighted to welcome him to our Board."

    "I am very excited to join Radient's Board of Director and look forward to supporting the development of its portfolio of promising IVD cancer test, vaccines and therapies," commented Dr. Beart. "The company is on a tremendous growth trajectory and I believe it offers a very promising future to physicians and their cancer patients, the business community and to RPC shareholders."
    Mar 11 11:57 AM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]

    I am long Radient and intend to keep my shares for at least a year because there are events forthcoming which might be negative or positive in the short run. In the long run, I believe Radient will go well into the single digits and possibly higher into double digits. Radient has to face de-listing. So what. It can still sell its stock.

    Radient is waiting for independent test result statistical analysis to compare its product to the present standard CEA test. It would not have been so public about it and would not lie about its possibilities if it did not think, or know, that it would be better than the CEA test.

    Sales will depend on convincing doctors and clinics to use its tests. So, sales might take six months to materialize.

    Radient has at least two spinoff companies that it owns which it will offer IPOs on. Those will boost the value of Radient since it owns most of the stock of the spinoff companies.

    Radient is doing business with a University of Florida medical doctor in cancer treatments using geno dna technology and will market that treatment.

    I am less impressed with AF's and the Street's negativity and inaccuracies and his opinionated bashing of Radient than I am over their less than clear press releases which they have cleared up.
    Mar 11 08:59 AM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    As I understand the problem, the exchange requires a $4mil nest egg.
    RPC just refinanced and has $7mil it is sitting on. The de-listing notice was based in part on last October's financial picture. If the exchange de-lists them, to me, IMHO, it just means that the Jan 7 and the de-listing are proof of the exchange being in bed with large short traders or drug companies trying to drive down the price of the stock like The Street with all of its bashing of RPC. Personally, I can not think of many reasons to sell short or even buy puts except as a hedge when there are so many companies with good news and reports. In fact, I think it is as stupid to sell short as it is to trade on margin. But the smart guys on wall street think it is okay I guess and manufacture bad news to make money selling short. I wonder if they did so when they crashed the market in 08 and bribed politicians to steal our tax dollars for their bailout. Maybe wall street should be renamed the sewer.
    Mar 10 10:47 AM | Likes Like |Link to Comment
  • Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
    RPC contacted Mayo to get samples of cancer specimens which had been diagnosed with the CEA testing, Mayo's results and analysis. RPC is testing the same samples with Onko and submitting the results to independent analysis and to Mayo. That has never been done before.

    The results are due out soon. IF (yes, that is a big IFFF) the tests show Onko is superior to CEA and sets a new standard and replaces CEA, fasten your seatbelt because RPC will sky rocket as medical doctors want the best testing product they can get, here and around the world. What are the CEA numbers and its influence on price? That will be RPCs.
    Mar 10 08:39 AM | Likes Like |Link to Comment
COMMENTS STATS
49 Comments
16 Likes